CBL-514 Developer
CBL-514 was developed by Chong Kun Dang Pharmaceutical Corp., a South Korean pharmaceutical company. 1, 2, 3, 4
The compound is a novel small-molecule injectable lipolysis agent designed to induce targeted adipocyte apoptosis for subcutaneous fat reduction. Based on the clinical trial registrations and published research, CBL-514 has progressed through Phase IIa and Phase IIb clinical development for abdominal subcutaneous fat reduction, with studies conducted between 2022 and 2026 2, 3, 4.
The drug has demonstrated significant efficacy in reducing abdominal subcutaneous fat volume and thickness through multiple randomized, placebo-controlled trials, with a favorable safety profile characterized primarily by mild-to-moderate injection site reactions 2, 3, 4.